Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Gen9

company

About

Gen9 provides gene synthesis technology that enables the high-throughput, automated production of DNA constructs.

  • 11 - 50

Details

Last Funding Type
Private Equity(PE)
Last Funding Money Raised
$21M
Industries
Biotechnology,Genetics,Manufacturing
Founded date
Jan 1, 2009
Number Of Employee
11 - 50
Operating Status
Active

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.

Gen9 was established in 2009 and is based in Cambridge, Massachusetts, United States.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$21M
Gen9 has raised a total of $21M in funding over 2 rounds. Their latest funding was raised on Apr 24, 2013 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 24, 2013 Private Equity(PE) $21M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Gen9 is funded by 1 investors. Agilent Technologies are the most recent investors.
Investor Name Lead Investor Funding Round
Agilent Technologies Private Equity(PE)